SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-21-251478
Filing Date
2021-08-19
Accepted
2021-08-19 16:02:16
Documents
12
Period of Report
2021-08-13
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Document Format Files

Seq Description Document Type Size
1 8-K d198481d8k.htm   iXBRL 8-K 22492
  Complete submission text file 0001193125-21-251478.txt   139931

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA apls-20210813.xsd EX-101.SCH 2889
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE apls-20210813_lab.xml EX-101.LAB 17374
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE apls-20210813_pre.xml EX-101.PRE 10951
5 EXTRACTED XBRL INSTANCE DOCUMENT d198481d8k_htm.xml XML 3208
Mailing Address 100 FIFTH AVENUE WALTHAM MA 02451
Business Address 100 FIFTH AVENUE WALTHAM MA 02451 617-977-5700
Apellis Pharmaceuticals, Inc. (Filer) CIK: 0001492422 (see all company filings)

IRS No.: 271537290 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38276 | Film No.: 211190109
SIC: 2834 Pharmaceutical Preparations